Switching antihypertensive therapy in times of COVID-19: why we should wait for the evidence

Eur Heart J. 2020 May 14;41(19):1857. doi: 10.1093/eurheartj/ehaa335.

Authors

Gabriela M Kuster^{1

2}, Stefan Osswald¹

Affiliations

¹ Department of Cardiology, University Hospital Basel, Petersgraben 4, 4031 Basel, Switzerland.
² Department of Biomedicine, University Hospital Basel and University of Basel, Hebelstrasse 20, 4031 Basel, Switzerland.

No abstract available

Publication types

Comment

MeSH terms

Antihypertensive Agents*
Betacoronavirus
COVID-19
Coronavirus Infections
Humans
Hypertension*
Pandemics
Pneumonia, Viral
SARS-CoV-2

Substances

Antihypertensive Agents